PATRITUMAB DERUXTECAN
UNII 3XPI7EG4W8

Substance Identification & Data

This profile provides standardized clinical and technical data for Patritumab Deruxtecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3XPI7EG4W8.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2227102-46-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3XPI7EG4W8

CAS Registry Number

2227102-46-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PATRITUMAB DERUXTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C136987

National Cancer Institute reference terminology for clinical and research data.

INN ID

11093

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-231

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Patritumab Deruxtecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PATRITUMAB DERUXTECAN

Common Names & Synonyms

ANTI-HER3 ANTIBODY-DRUG CONJUGATE U3 1402

IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER3) (HUMAN MONOCLONAL U3-1287 .GAMMA.1-CHAIN), COMPLEX WITH HUMAN MONOCLONAL U3-1287 .KAPPA.-CHAIN, DIMER, OCTAKIS(THIOETHER) WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY)METHYL)GLYCINAMIDE

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB3 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3, HER3)), HOMO SAPIENS MONOCLONAL ANTIBODY, CONJUGATED TO DERUXTECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE; GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-447) (VH (HOMO SAPIENS IGHV4-34*01 (99.0%) -(IGHD) - IGHJ2*01 (100%)) (8.7.11) (1-117) - HOMO SAPIENS IGHG1*03 (100%) G1M3, NG1M1 (CH1 R120 (214) (118-215), HINGE 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (123-452)), (220-220')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS (1'-220') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (95.0%) -IGKJ1*01 (100%)) (12.3.9) (1'-113') - HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (159), V101 (197) (114'-220')); DIMER (226-226'':229-229'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELL LINE, GLYCOFORM ALFA; CONJUGATED, ON AN AVERAGE OF 8 CYSTEINYL, TO DERUXTECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE

PATRITUMAB DERUXTECAN [INN]

PATRITUMAB DERUXTECAN [JAN]

PATRITUMAB DERUXTECAN [USAN]

PATRITUMAB DERUXTECAN [WHO-DD]